Skip to main navigation Skip to search Skip to main content

Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review

  • Teodor Salmen
  • , Claudia Gabriela Potcovaru
  • , Ioana Cristina Bica
  • , Rosaria Vincenza Giglio
  • , Angelo Maria Patti
  • , Roxana Adriana Stoica
  • , Marcello Ciaccio
  • , Mohamed El-Tanani
  • , Andrej Janež
  • , Manfredi Rizzo
  • , Florentina Gherghiceanu
  • , Anca Pantea Stoian
  • Carol Davila University of Medicine and Pharmacy
  • University of Palermo
  • Ambulatorio fisiopatologia digestiva AOU Paolo Giaccone
  • “Vittorio Emanuele II” Hospital
  • University of Ljubljana

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Background This systematic review is registered with CRD42024507397 protocol number and aims to compare the known data about retatrutide on long-term cardiovascular (CV) protection with tirzepatide, an incretin with recent proven CV benefits. Material and Methods The inclusion criteria were (i) original full-text articles that are randomized control or clinical trials; (ii) published within the last ten years; (iii) published in English; and (iv) conducted on adult human populations. The exclusion criteria were articles deruled on cell cultures or mammals. Studies were selected if they (1) included patients with type 2 diabetes mellitus (DM) and CV risk; (2) patients that received either tirzepatide or retatrutide; and (3) provided sufficient information such as the corresponding 95% confidence intervals or at least a sufficient p-value. Studies were excluded if they were a letter to the editor, expert opinions, case reports, meeting abstracts, or reviews; redundant publications; or needed more precise or complete data. Results The seven included studies were assessed for bias with the Newcastle Ottawa scale, heterogenous, and emphasized the potential CV beneficial effect of type 2 DM (T2DM) therapies (glycemia, glycated A1c hemoglobin, body weight, lipid profile, blood pressure and renal parameter). Discussions Further, longer follow-up studies are necessary to verify the long-term CV protection, standardize the specific aspects of CV risk, and compare with subjects without T2DM for a more integrative interpretation of the CV effects independent of the improvement of metabolic activity.

Original languageEnglish
Article number1322
JournalPharmaceuticals
Volume17
Issue number10
DOIs
StatePublished - Oct 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • cardiovascular disease
  • retatrutide
  • tirzepatide
  • type 2 diabetes mellitus

Fingerprint

Dive into the research topics of 'Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review'. Together they form a unique fingerprint.

Cite this